Results 11 to 20 of about 1,436,444 (347)

Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL [PDF]

Frontiers in Immunology
IntroductionChimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in treating B-cell malignancies, including acute lymphoblastic leukemia (B-ALL).
Jennifer Bolsée, Benjamin Violle, Céline Jacques-Hespel, Thuy Nguyen, Caroline Lonez, Eytan Breman   +5 more
doaj   +4 more sources

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Nature Communications, 2019
Immunotherapy with chimeric antigen receptor-engineered T-cells (CAR-T) is under investigation in multiple myeloma. There are reports of myeloma remission after CD19 CAR-T therapy, although CD19 is hardly detectable on myeloma cells by flow cytometry (FC)
T. Nerreter, Sebastian Letschert, Ralph Götz, S. Doose, Sophia Danhof, H. Einsele, M. Sauer, M. Hudecek   +7 more
semanticscholar   +2 more sources

Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flow cytometric detection of minimal residual disease

British Journal of Haematology, 2021
CD19‐directed treatment in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry (MFC) application for minimal/measurable residual disease (MRD) assessment in ...
E. Mikhailova, A. Semchenkova, O. Illarionova, S. Kashpor, V. Brilliantova, E. Zakharova, E. Zerkalenkova, A. Zangrando, N. Bocharova, L. Shelikhova, Y. Diakonova, V. Zhogov, R. Khismatullina, O. Molostova, B. Buldini, E. Raykina, S. Larin, Y. Olshanskaya, N. Miakova, G. Novichkova, M. Maschan, A. Popov   +21 more
semanticscholar   +2 more sources

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

Biomedicines, 2023
Background: Therapeutic options for CD19+ relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed.
Audrey Grain, Jocelyn Ollier, Thierry Guillaume, Patrice Chevallier, Baptiste Le Calvez, Marion Eveillard, Béatrice Clémenceau   +6 more
doaj   +2 more sources

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. [PDF]

, 2022
Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic ...
Álvarez-Vallina, Luis, Rubio Pérez, Laura, Blanco, Belén   +2 more
core   +2 more sources

Targeting the CD19/CD21 complex on B cells in the mixed lymphocyte reaction [PDF]

, 2022
B cells exert antigen presenting functions at the crossroad between immune activation and tolerance induction, a fate notably governed by the B Cell Receptor (BCR) response regulator CD19/CD21 complex. This duality in B cells raises a particular interest
Broc, Sabine
core   +1 more source

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors [PDF]

Journal of Translational Medicine, 2013
Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis,
De Oliveira, SN, Wang, J, Ryan, C, Morrison, SL, Kohn, DB, Hollis, RP   +5 more
openaire   +6 more sources

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies [PDF]

Journal of Clinical Investigation, 2016
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients ...
Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F. Lacey, Jan J. Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David L. Porter, Carl H. June, Stephan A. Grupp, Saar Gill   +20 more
openaire   +2 more sources

Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells

International Journal of Nanomedicine, 2023
CAR-T cell therapy is effective in the treatment of certain hematological malignancies, and the expansion and functional persistence of CAR-T cells in vivo are crucial to clinical efficacy. The aim of this study was to investigate the potential of extracellular vesicles (EVs) modified with the CAR antigen to promote the efficacy of CAR-T cells in vivo ...
Yuanyuan Zhang, Tong Ge, Meijuan Huang, Yun Qin, Tianjiao Liu, Wei Mu, Gaoxiang Wang, Lijun Jiang, Tongjuan Li, Lei Zhao, Jue Wang   +10 more
openaire   +4 more sources

RELIABLE FLOW CYTOMETRY METHOD FOR MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA AFTER BLINATUMOMAB THERAPY

Hematology, Transfusion and Cell Therapy, 2023
Introduction: The recent active use of immunotherapy based on CD19/CD3 bispecific T-cell engager (blinatumomab), brings significant problems on monitoring Minimal Residual Disease (MRD) based on Multiparameter Flow Cytometry (MFC), due to possible CD19 ...
RM Pontes, FM Furtado, SCR Franco, RA Toscano, TF Nunes, ACS Dias, JCM Cordoba, ACMDS Junior, R Camargo, IMM Quezado   +9 more
doaj   +1 more source